Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Verbal episodic memory in children undergoing temporal lobe epilepsy surgery: a one-year follow-up study.

Revista de neurologia·2024
Same author

Smokers and risk of hospital death by COVID calculated with SAVANA's natural language processing in the Castilla-La Mancha area.

Revista clinica espanola·2023
Same author

Evaluation of connectivity measures to identify Seizure Onset and Propagation Zones in Refractory Epilepsy: A Case study with two different Post- Surgical Outcomes<sup></sup>.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2023
Same author

N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment.

European review for medical and pharmacological sciences·2022
Same author

Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study.

Journal of investigational allergology & clinical immunology·2021
Same author

Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2021

Related Experiment Video

Updated: Jun 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Roflumilast for COPD.

J L Izquierdo1, J Aparicio

  • 1Pulmonology Department, Hospital General Universitario, Guadalajara, Spain. jlizquierdo@sescam.org

Drugs of Today (Barcelona, Spain : 1998)
|January 13, 2011
PubMed
Summary

Roflumilast, a phosphodiesterase PDE4 inhibitor, treats chronic obstructive pulmonary disease (COPD) with chronic bronchitis. It improves lung function and reduces exacerbations in patients with COPD, offering a new therapeutic option.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) with chronic bronchitis involves airway inflammation, reduced lung function, and exacerbations.
  • These exacerbations significantly impair quality of life, accelerate disease progression, and increase mortality.
  • Chronic cough and sputum are key indicators of the underlying inflammation in COPD.

Purpose of the Study:

  • To evaluate roflumilast, a phosphodiesterase PDE4 inhibitor, for treating COPD associated with chronic bronchitis.
  • To assess the drug's efficacy in improving lung function and reducing exacerbation frequency.
  • To determine if roflumilast is effective as an add-on therapy to existing COPD treatments.

Main Methods:

  • Clinical trials were conducted to assess roflumilast's impact on patients with COPD and chronic bronchitis history.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

  • Lung function parameters and the frequency of exacerbations requiring medical intervention were primary endpoints.
  • The study also examined roflumilast's effects when combined with long-acting bronchodilators like tiotropium and salmeterol.

    • Main Results:

    • Roflumilast demonstrated significant improvements in lung function for patients with COPD and chronic bronchitis.
    • The drug effectively reduced the frequency of exacerbations requiring medical intervention.
    • These benefits were observed even when roflumilast was added to standard long-acting bronchodilator treatments.

    Conclusions:

    • Roflumilast is an effective anti-inflammatory treatment for a specific COPD phenotype (COPD with chronic bronchitis).
    • It offers a valuable therapeutic option for managing lung function and reducing exacerbations.
    • The drug is generally well-tolerated, with manageable side effects, primarily gastrointestinal.